CD19 and acute lymphoblastic leukemia: In acute lymphocytic leukemia (ALL), bispecific antibodies utilized for the recruitment of cytotoxic T cells to CD19+ leukemic cells have been shown to be an effective approach, and are now part of the standard-of-care [7].